The Experience of Using the Drug Inclusiran in Patients With an Extremely High Risk Of Developing Cardiovascular Complications in The Acute Period of Myocardial Infarction

Aim         To evaluate the effect of intensive lipid-lowering therapy (LLT), including inclisiran prescribed in the acute phase of ST-segment elevation myocardial infarction (STEMI), on lipid profile in patients with extremely high risk (EHR) of cardiovascular complications (CVC).

Material and methods        This prospective single-center clinical study included 20 patients (mean age 58.45±2.43 years, 75% men) with EHR of CVC and STEMI. All patients were prescribed combination LLT, including inclisiran. Lipid profile parameters were assessed 8±1 days after the initiation of therapy. Statistical analysis was performed with a STATISTICA 13.3 software.

Results   Analysis of the lipid-lowering effect of inclisiran showed a significant decrease in total cholesterol from 5.13±0.29 to 2.81±0.26 mmol/l (45.2%; p<0.001) and low-density lipoprotein cholesterol (LDL-C) from 3.59±0.23 to 1.60±0.23 mmol/l (55.4%; p<0.001).

Conclusion          The study showed a possibility of achieving statistically and clinically significant reduction in LDL-C in patients with EHR of CVC in the acute period of STEMI with the combination therapy including inclisiran during the inpatient treatment.

1. Polyakova E.A., Lapin S.V., Mazing A.V., Lisker A.V., Sitnikova M.Yu., Fedotov P.A. et al. Inclisiran use in clinical practice in patients with dyslipidemia: first results. Russian Medical Journal. 2023;9:18–29.

2. Korzukhin A.Yu., Yuldoshev D.R., Troshina A.A., Khuramshina L.R., Guzarik V.N., Dyrnaeva A.D. et al. Type 2 myocardial infarction: diagnostic and therapeutic difficulties in modern cardiology. Complex Issues of Cardiovascular Diseases. 2023;12(3):84–97. DOI: 10.17802/2306-1278-2023- 12-3-84-97

3. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–97. DOI: 10.15829/1560-4071-2023-5471

4. Voevoda M.I., Gurevich V.S., Ezhov M.V., Sergienko I.V. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57–62. DOI: 10.18087/cardio.2022.6.n2115

5. Martsevich S.Yu. Recurrent myocardial infarction as an unsolved problem of evidence-based medicine. Cardiovascular Therapy and Prevention. 2024;23(6):72–80. DOI: 10.15829/1728-8800-2024-4019

6. Boytsov S.A., Shakhnovich R.M., Tereschenko S.N., Erlikh A.D., Kukava N.G., Pevsner D.V. et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12–22. DOI: 10.18087/cardio.2022.7.n2051

7. Boytsov S.A., Voevoda M.I., Gurevich V.S., Duplyakov D.V., Ezhov M.V., Karpov Yu.A. et al. Actual questions of intensification of lipid-lowering therapy resolution of the national scientific council of experts. Athero sclerosis and Dyslipidemias. 2022;1(46):64–70.

8. Blokhina A.V., Ershova A.I., Meshkov A.N., Akhmedzhanov N.M., Ivanova A.A., Guseinova K.A. et al. Lipid-lowering therapy: modern possibilities and real clinical practice. Cardiovascular Therapy and Prevention. 2022;21(8):48–58. DOI: 10.15829/1728-8800-2022-3369

9. Novartis Pharma. General characteristics of the medicinal product Sibrava RU LP-No. (000689) - (RG-RU) dated 02.07.2024. Av. at: https://www.novartis.com/ru-ru/sites/novartis_ru/ files/2024-07-02 131_Sybrava SOL 284 mg SmPC_0006_v5.0_ RUr.pdf.

10. Sapina A.I., Varlamova Yu.Yu., Papyrina M.G., Bezymyannyy A.S., Vasilyeva E.Yu. Observational study of inclisiran effectiveness in Moscow healthcare. Russian Journal of Cardiology. 2023;28(12):62–7. DOI: 10.15829/1560-4071-2023-5687

11. Korobka V.L., Khripun A.V., Malevannyy M.V., Kulikovskikh Ya.V. The short-term and mid-term outcomes of percutaneous coronary intervention with implantation of bioresorbable vascular scaffolds for STEMI treatment. Endovascular Surgery. 2015;2(1–2):58–68.

12. Averkov O.V., Duplyakov D.V., Gilyarov M.Yu., Novikova N.A., Shakhno vich R.M., Yakovlev A.N. et al. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):251–310. DOI: 10.15829/29/1560-4071-2020-4103

13. Dedov I.I., Melnichenko G.A. National guidelines. Endocrinology. - M.: GEOTAR-Media; 2022. - 1112p. ISBN 978-5-9704-6751-0

14. Ministry of Health of Russian Federation. Clinical guidelines. Type 2 diabetes mellitus in adults. 2022. Av. at: https://cr.minzdrav.gov. ru/view-cr/290_2.

15. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Russian Journal of Cardiology. 2019;24(8):151– 226. DOI: 10.15829/1560-4071-2019-8-151-226

16. Adzhiev R.N., Safarova M.S., Ezhov M.V., Matchin Yu.G. Aggressive lipid-lowering therapy before and after myocardial revascularization in patients with stable coronary heart disease. Medical Council. 2013;4– 2:55–61.

17. Filatova A.Yu., Osokina A.K., Potekhina A.V., Romasov I.V., Kotkina T.I., Shchinova A.M. et al. Analysis of the causes of repeat stenosis of the coronary arteries after elective stenting in patients with stable angina pectoris. Therapeutic archive. 2021;93(1):59–65. DOI: 10.26442/004036 60.2021.01.200594

18. Sud M, Han L, Koh M, Abdel-Qadir H, Austin PC, Farkouh ME et al. Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2020;76(12):1440–50. DOI: 10.1016/j.jacc.2020.07.033

19. Tang L, Chen H, Hu X, Fang Z, Liao X, Zhou X et al. Intensive Lipid‐Lowering Therapy as per the Latest Dyslipidemia Management Guideline in Predicting Favorable Long‐Term Clinical Outcomes

20. in Patients Undergoing Coronary Artery Bypass Grafting: A Retrospective Cohort Study. Journal of the American Heart Association. 2023;12(20):e029397. DOI: 10.1161/JAHA.123.029397

21. Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. European Heart Journal. 2015;36(32):2147–59. DOI: 10.1093/eurheartj/ehv205

22. Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal: Acute Cardiovascular Care. 2022;11(12):939–49. DOI: 10.1093/ehjacc/zuac123

23. Pogran E, Burger AL, Zweiker D, Kaufmann CC, Muthspiel M, Rega-Kaun G et al. Lipid-Lowering Therapy after Acute Coronary Syndrome. Journal of Clinical Medicine. 2024;13(7):2043. DOI: 10.3390/jcm13072043

24. Krychtiuk KA, Claeys MJ, Gencer B, Mach F. In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons. EuroIntervention. 2023;19(4):e283–5. DOI: 10.4244/EIJ-E-23-00014

25. Ministry of Health of the Russian Federation. Acute myocardial infarction with elevation of the ST segment of the electrocardiogram. Clinical recommendations. 2024. Av. at: https://cr.minzdrav.gov.ru/view-cr/157_5.

26. Ministry of Health of Russian Federation. Clinical recomendations. Acute coronary syndrome without ST segment elevation electrocardiogram. 2024. Av. at: https://scardio.ru/content/Guidelines/2024_09_26.pdf.